117 related articles for article (PubMed ID: 38558415)
21. [The value of machine learning models based on biparametric MRI for diagnosis of prostate cancer and clinically significant prostate cancer].
Qiao XM; Hu CH; Hu S; Hu CH; Wang XM; Shen JK; Ji LB; Song Y; Bao J
Zhonghua Yi Xue Za Zhi; 2023 May; 103(19):1446-1454. PubMed ID: 37198106
[No Abstract] [Full Text] [Related]
22. Quantitative Analysis of Diffusion Weighted Imaging May Improve Risk Stratification of Prostatic Transition Zone Lesions.
Engel H; Oerther B; Reisert M; Kellner E; Sigle A; Gratzke C; Bronsert P; Krauss T; Bamberg F; Benndorf M
In Vivo; 2022; 36(5):2323-2331. PubMed ID: 36099133
[TBL] [Abstract][Full Text] [Related]
23. Avoiding Unnecessary Biopsy: MRI-based Risk Models versus a PI-RADS and PSA Density Strategy for Clinically Significant Prostate Cancer.
Deniffel D; Healy GM; Dong X; Ghai S; Salinas-Miranda E; Fleshner N; Hamilton R; Kulkarni G; Toi A; van der Kwast T; Zlotta A; Finelli A; Perlis N; Haider MA
Radiology; 2021 Aug; 300(2):369-379. PubMed ID: 34032510
[TBL] [Abstract][Full Text] [Related]
24. A prospective study of the prostate health index density and multiparametric magnetic resonance imaging in diagnosing clinically significant prostate cancer.
Chen Y; Xu D; Ruan M; Li H; Lin G; Song G
Investig Clin Urol; 2023 Jul; 64(4):363-372. PubMed ID: 37417561
[TBL] [Abstract][Full Text] [Related]
25.
Yang J; Li J; Xiao L; Zhou M; Fang Z; Cai Y; Tang Y; Hu S
Cancer Imaging; 2023 Sep; 23(1):81. PubMed ID: 37667341
[TBL] [Abstract][Full Text] [Related]
26. A 4K score/MRI-based nomogram for predicting prostate cancer, clinically significant prostate cancer, and unfavorable prostate cancer.
Wagaskar VG; Sobotka S; Ratnani P; Young J; Lantz A; Parekh S; Falagario UG; Li L; Lewis S; Haines K; Punnen S; Wiklund P; Tewari A
Cancer Rep (Hoboken); 2021 Aug; 4(4):e1357. PubMed ID: 33661541
[TBL] [Abstract][Full Text] [Related]
27. Development and validation of a nomogram based on biparametric MRI PI-RADS v2.1 and clinical parameters to avoid unnecessary prostate biopsies.
Wang Y; Wang L; Tang X; Zhang Y; Zhang N; Zhi B; Niu X
BMC Med Imaging; 2023 Aug; 23(1):106. PubMed ID: 37582697
[TBL] [Abstract][Full Text] [Related]
28. Based on PI-RADS v2.1 combining PHI and ADC values to guide prostate biopsy in patients with PSA 4-20 ng/mL.
Huang H; Liu Z; Ma Y; Shao Y; Yang Z; Duan D; Zhao Y; Wen S; Tian J; Liu Y; Wang Z; Yue D; Wang Y
Prostate; 2024 Mar; 84(4):376-388. PubMed ID: 38116741
[TBL] [Abstract][Full Text] [Related]
29. Diffusion-weighted imaging predicts upgrading of Gleason score in biopsy-proven low grade prostate cancers.
Park SY; Oh YT; Jung DC; Cho NH; Choi YD; Rha KH; Hong SJ
BJU Int; 2017 Jan; 119(1):57-66. PubMed ID: 26823024
[TBL] [Abstract][Full Text] [Related]
30. Multi-institutional analysis of clinical and imaging risk factors for detecting clinically significant prostate cancer in men with PI-RADS 3 lesions.
Fang AM; Shumaker LA; Martin KD; Jackson JC; Fan RE; Khajir G; Patel HD; Soodana-Prakash N; Vourganti S; Filson CP; Sonn GA; Sprenkle PC; Gupta GN; Punnen S; Rais-Bahrami S
Cancer; 2022 Sep; 128(18):3287-3296. PubMed ID: 35819253
[TBL] [Abstract][Full Text] [Related]
31. Clinico-radiological characteristic-based machine learning in reducing unnecessary prostate biopsies of PI-RADS 3 lesions with dual validation.
Kan Y; Zhang Q; Hao J; Wang W; Zhuang J; Gao J; Huang H; Liang J; Marra G; Calleris G; Oderda M; Zhao X; Gontero P; Guo H
Eur Radiol; 2020 Nov; 30(11):6274-6284. PubMed ID: 32524222
[TBL] [Abstract][Full Text] [Related]
32. Prostate biopsy in the era of MRI-targeting: towards a judicious use of additional systematic biopsy.
Deniffel D; Perlis N; Ghai S; Girgis S; Healy GM; Fleshner N; Hamilton R; Kulkarni G; Toi A; van der Kwast T; Zlotta A; Finelli A; Haider MA
Eur Radiol; 2022 Nov; 32(11):7544-7554. PubMed ID: 35507051
[TBL] [Abstract][Full Text] [Related]
33. [Application of dynamic contrast enhanced status in multiparametric magnetic resonance imaging for prostatic cancer with PI-RADS 4 lesion].
Yuan CW; Li R; Li ZH; Liu Y; Shan GZ; Li XS; Zhou LQ
Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Oct; 55(5):838-842. PubMed ID: 37807737
[TBL] [Abstract][Full Text] [Related]
34. Prevalence of Prostate Cancer in PI-RADS Version 2.1 Transition Zone Atypical Nodules Upgraded by Abnormal DWI: Correlation With MRI-Directed TRUS-Guided Targeted Biopsy.
Lim CS; Abreu-Gomez J; Carrion I; Schieda N
AJR Am J Roentgenol; 2021 Mar; 216(3):683-690. PubMed ID: 32755208
[No Abstract] [Full Text] [Related]
35. Association Between Prostate Imaging Reporting and Data System (PI-RADS) Score for the Index Lesion and Multifocal, Clinically Significant Prostate Cancer.
Stabile A; Dell'Oglio P; De Cobelli F; Esposito A; Gandaglia G; Fossati N; Brembilla G; Cristel G; Cardone G; Deho' F; Losa A; Suardi N; Gaboardi F; Del Maschio A; Montorsi F; Briganti A
Eur Urol Oncol; 2018 May; 1(1):29-36. PubMed ID: 31100225
[TBL] [Abstract][Full Text] [Related]
36. Impact of mandated prospectively reported apparent diffusion coefficient values on the rates of positivity for clinically significant prostate cancer by PI-RADS score.
Shaish H; Casals R; Ahmed F; Makkar J; Wenske S
Acta Radiol; 2021 Jan; 62(1):139-144. PubMed ID: 32312102
[TBL] [Abstract][Full Text] [Related]
37. Diagnostic value of combining PI-RADS v2.1 with PSAD in clinically significant prostate cancer.
Wei X; Xu J; Zhong S; Zou J; Cheng Z; Ding Z; Zhou X
Abdom Radiol (NY); 2022 Oct; 47(10):3574-3582. PubMed ID: 35788882
[TBL] [Abstract][Full Text] [Related]
38. Combination of prostate imaging reporting and data system (PI-RADS) score and prostate-specific antigen (PSA) density predicts biopsy outcome in prostate biopsy naïve patients.
Washino S; Okochi T; Saito K; Konishi T; Hirai M; Kobayashi Y; Miyagawa T
BJU Int; 2017 Feb; 119(2):225-233. PubMed ID: 26935594
[TBL] [Abstract][Full Text] [Related]
39. Added Value of Prostate-specific Antigen Density in Selecting Prostate Biopsy Candidates Among Men with Elevated Prostate-specific Antigen and PI-RADS ≥3 Lesions on Multiparametric Magnetic Resonance Imaging of the Prostate: A Systematic Assessment by PI-RADS Score.
Pellegrino F; Stabile A; Sorce G; Quarta L; Robesti D; Cannoletta D; Cirulli G; Barletta F; Scuderi S; Mazzone E; de Angelis M; Brembilla G; De Cobelli F; Salonia A; Montorsi F; Briganti A; Gandaglia G
Eur Urol Focus; 2023 Oct; ():. PubMed ID: 37865591
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of relationships between the final Gleason score, PI-RADS v2 score, ADC value, PSA level, and tumor diameter in patients that underwent radical prostatectomy due to prostate cancer.
Gündoğdu E; Emekli E; Kebapçı M
Radiol Med; 2020 Sep; 125(9):827-837. PubMed ID: 32266690
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
